Figure 7. Serum AAT reductions in healthy human volunteers treated with ARO-AAT.

Human subjects in a phase I dose escalating study were given a single SC injection of a fixed dose of 35 mg, 100 mg, 200 mg, or 300 mg ARO-AAT or placebo (n = 4). (A) Serum was collected and AAT measured at the indicated times, shown as the group mean ± SEM. (B) The doses were then divided by the subjects’ body weight to assess the equivalent mg/kg doses. The lower limit of quantitation was 0.09 g/L AAT.